Treatment of Comorbid Insomnia and Depression or Anxiety

Introduction to Treatment

The American Academy of Sleep Medicine recommends eszopiclone, a non-benzodiazepine hypnotic, for sleep onset and maintenance insomnia, acting as a GABA receptor agonist, primarily used for patients with comorbid insomnia and depression or anxiety 1

The American Academy of Sleep Medicine suggests eszopiclone dosing of 2-3 mg at bedtime for adults and 1 mg for elderly or those with hepatic impairment, and recommends administering eszopiclone on an empty stomach to maximize effectiveness 1
Elderly patients should be started on eszopiclone at 1mg, according to the American Academy of Sleep Medicine, due to increased risk of adverse effects 1

The American Academy of Sleep Medicine advises cautious dosing in elderly patients, with escitalopram limited to 20mg/day in patients over 60 years due to risk of QT interval prolongation, and eszopiclone started at 1mg in elderly or debilitated patients 1
The European Society of Cardiology recommends limiting citalopram to 20mg/day in patients over 60 years due to the increased risk of QT interval prolongation 2, 3
Citalopram monotherapy (up to 20mg/day) is recommended for the treatment of depression in elderly patients due to its better safety profile and fewer medication interactions 2

Patients with liver disease may have altered drug metabolism, potentially increasing the risk of adverse effects, and should be considered for lower doses and closer monitoring, according to the American Academy of Sleep Medicine 1
The European Society of Cardiology recommends close monitoring in the first 24-48 hours after initiation or dose adjustment of medications like citalopram, with at least yearly follow-up for medication effects and adverse reactions, particularly in elderly patients 4
Patients should be informed that full therapeutic effect may take several weeks to develop, and caution should be exercised when combining medications due to risk of adverse effects 2
The American Geriatrics Society implies that elderly patients are at greater risk for developing hyponatremia with SSRIs, and monitoring sodium levels is crucial, especially in patients taking diuretics or who are volume-depleted 4
The European Heart Journal recommends monitoring for signs of bleeding, particularly in elderly patients on multiple medications, due to the increased risk of bleeding events with citalopram 4
Patients should be monitored carefully for signs of serotonin syndrome (confusion, agitation, tremor, hyperthermia) and excessive sedation, according to the European Society of Cardiology and the European Society for Medical Oncology 3, 5

The American Psychiatric Association suggests that sertraline has a lower potential for drug interactions among SSRIs, making it safer for elderly patients with multiple comorbidities 4
Escitalopram is well-tolerated in elderly patients with a favorable side effect profile, according to the European Heart Journal 4
For insomnia, mirtazapine or trazodone are considered safer alternatives to antihistamines in elderly patients, with a lower risk of adverse effects and interactions, according to clinical guidelines 6
For anxiety, sertraline monotherapy (initial dose 25-50mg) is recommended, with consideration of alternative treatments due to potential interactions and side effects, as suggested by the American Family Physician and other clinical guidelines 2, 6
Benzodiazepines with a short duration of action in low doses for limited periods may be considered for anxiety, as suggested by the American Urological Association 7

Clorfeniramina and orfenadrina have significant anticholinergic effects, which can cause symptoms such as confusion, dizziness, dry mouth, blurred vision, constipation, and urinary retention, especially in elderly patients, according to the European Society for Medical Oncology and the American Family Physician 5, 2
The combination of medications such as citalopram, sertralina, chlorpheniramine, and orphenadrine can produce symptoms mimicking alcohol intoxication, including slurred speech and excessive drowsiness, and increase the risk of falls, as noted by the European Society for Medical Oncology and the American Family Physician 5, 8, 2, 9
Medications should be started at very low doses (25-50% of the standard dose) and monitored closely for signs of toxicity, especially in the first 24-48 hours after initiation or dose adjustment, as recommended by the Journal of the American Academy of Child and Adolescent Psychiatry 8